Borg Frances A, Dasgupta Bhaskar
Department of Rheumatology, Southend University Hospital, Essex, UK.
Best Pract Res Clin Rheumatol. 2009 Jun;23(3):325-37. doi: 10.1016/j.berh.2009.04.001.
Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are characterised by systemic inflammation and critical ischaemia. GCA is a medical emergency. Neuro-ophthalmic complications occur early, with permanent vision loss in up to a fifth of patients, resulting mainly from failure of prompt recognition and treatment. Diagnosis of large vessel vasculitis is often delayed due to poor recognition of early, often non-specific symptoms. Laboratory inflammatory markers are often discordant with disease activity. Modern imaging techniques show promise in diagnosis and disease monitoring, improving our understanding of major artery involvement in large vessel vasculitis. However, in practice, their role is still unclear. The mainstay of therapy remains corticosteroids. Experience using conventional disease-modifying drugs is mixed, and biological therapies require further evaluation for their steroid-sparing potential.
巨细胞动脉炎(GCA)和大动脉炎(TA)的特征是全身性炎症和严重缺血。GCA是一种医疗急症。神经眼科并发症出现较早,多达五分之一的患者会出现永久性视力丧失,主要原因是未能及时识别和治疗。由于对早期往往不具特异性的症状认识不足,大血管血管炎的诊断常常延迟。实验室炎症标志物往往与疾病活动不一致。现代成像技术在诊断和疾病监测方面显示出前景,增进了我们对大血管血管炎中主要动脉受累情况的了解。然而,在实际应用中,其作用仍不明确。治疗的主要手段仍然是皮质类固醇。使用传统疾病改善药物的经验不一,生物疗法在节省类固醇方面的潜力需要进一步评估。